Critical reviews of 1470-nm laser vaporization on benign prostatic hyperplasia

Benign prostatic hyperplasia (BPH) is recognized as the common chronic disease that affect majority of men in their elder ages. Nevertheless, there are no effective documents for BPH treatment. Even though great progression has been made on BPH by laser surgery, it also faces several challenges. In this study, our aims were to explore the effects of 1470-nm laser vaporization on BPH. For the research, a total of 170 BPH patients were enrolled. A 1470-nm laser vaporization apparatus was purchased for the surgery. The indicators such as serum sodium, international prostate symptom score (IPSS), Quality of life (QOL), maximum flow rate (Qmax), prostate specific antigen (PSA), and average Post-void Residual Volume (PVR) were detected for evaluating the prostate function. The operation was successful in all 170 patients, neither of whom converted to transurethral resection of the prostate (TURP) nor to open surgery. The surgery time was 52.3 ± 5.6 min, the laser emission time was 35.6 ± 3.2 min, the energy consumption was 254.1 ± 19.3 kJ. The level of serum sodium showed no significant difference between the pre- and post-operation. Qmax was significantly increased in post-operation, while IPSS, QOL, PVR, and PSA were significantly decreased in the post-operation. The 1470-nm laser vaporization treatment protected patients against BPH, indicating that 1470-nm laser vaporization might be important on treating BPH, which provided solid foundation for further clinical treatment.